What are the definitions and recommended management strategies for resistant and refractory hypertension?

Definition and Management of Resistant/Refractory Hypertension

Resistant hypertension is defined as blood pressure ≥130/80 mmHg despite concurrent use of 3 antihypertensive agents at maximal or maximally tolerated doses (including a diuretic), or controlled BP requiring ≥4 medications; add low-dose spironolactone (25 mg daily) as the fourth-line agent if eGFR >45 mL/min/1.73 m² and potassium <4.5 mmol/L. 1, 2

Definition

Resistant Hypertension

• BP ≥130/80 mmHg on ≥3 antihypertensive drugs of different classes at optimal doses, including:
  • A long-acting calcium channel blocker (CCB)
  • A renin-angiotensin system (RAS) blocker (ACE inhibitor or ARB)
  • A diuretic (preferably thiazide-like: chlorthalidone or indapamide)
• OR controlled BP requiring ≥4 medications 3, 1, 2

Refractory Hypertension

• BP remains uncontrolled despite ≥5 antihypertensive agents at maximal doses, including:
  • A long-acting thiazide-like diuretic
  • A mineralocorticoid receptor antagonist (MRA)
• This represents an extreme phenotype with significantly higher cardiovascular risk 4, 5

Critical distinction: The 2024 ESC and 2025 AHA/ACC guidelines now use the lower BP threshold of 130/80 mmHg (not the older 140/90 mmHg), which increases the prevalence of resistant hypertension to approximately 8.5-20% of treated hypertensive adults 2.

Exclude Pseudoresistance FIRST

Before diagnosing true resistant hypertension, you must systematically rule out:

1. Inaccurate BP Measurement

• Confirm with 24-hour ambulatory BP monitoring (ABPM) - gold standard
• If ABPM unavailable, use home BP monitoring (HBPM)
• Exclude white coat hypertension (elevated office BP but controlled out-of-office readings) 1, 6, 5

2. Medication Nonadherence

• Use pharmacy refill data, pill counts
• Consider therapeutic drug monitoring when available
• Address cost barriers and side effects 6, 2

3. Suboptimal Treatment Regimen

• Ensure appropriate drug classes at maximal tolerated doses
• Replace HCTZ with chlorthalidone or indapamide (more effective) 2, 5
• Use loop diuretics if eGFR <30 mL/min/1.73 m² 7

4. Interfering Substances/Medications

• NSAIDs, decongestants, oral contraceptives, corticosteroids
• Excessive alcohol, sodium intake
• Stimulants, illicit drugs 2, 5

5. Secondary Hypertension

Screen for:

• Primary aldosteronism (most common in resistant hypertension)
• Obstructive sleep apnea (present in 60-80% of resistant cases)
• Renal artery stenosis
• Chronic kidney disease
• Pheochromocytoma
• Cushing syndrome 1, 2, 7

Management Algorithm

Step 1: Optimize Baseline Triple Therapy

Ensure maximal doses of:

• RAS blocker (ACE inhibitor or ARB - never combine both)
• Long-acting CCB (amlodipine, nifedipine)
• Thiazide-like diuretic (chlorthalidone 12.5-25 mg or indapamide 1.25-2.5 mg preferred over HCTZ) 1, 2, 5

Plus intensive lifestyle modification:

• Sodium restriction <2,400 mg/day (ideally <1,500 mg/day)
• Weight loss if BMI >25
• Regular aerobic exercise
• Limit alcohol intake
• DASH dietary pattern 1, 6, 5

Step 2: Add Mineralocorticoid Receptor Antagonist (Fourth-Line)

Spironolactone 25 mg daily is the preferred fourth-line agent with the strongest evidence for BP reduction 1, 6, 2

Requirements:

• eGFR ≥45 mL/min/1.73 m²
• Serum potassium <4.5 mmol/L
• Monitor potassium and creatinine within 1-2 weeks, then regularly 1, 7

Alternatives if spironolactone contraindicated or not tolerated:

• Eplerenone 50-100 mg daily (less potent but fewer side effects)
• Amiloride 5-10 mg daily
• Doxazosin 4-8 mg daily
• Bisoprolol 5-10 mg daily (if heart rate >70 bpm)
• Clonidine 0.1-0.3 mg twice daily or weekly patch 1, 8, 7

Step 3: Additional Agents for Refractory Hypertension

If BP remains uncontrolled on 4 agents:

Check heart rate:

• If ≥70 bpm: Add beta-blocker (metoprolol succinate, bisoprolol, carvedilol) or combined α-β-blocker (labetalol)
• If <70 bpm: Consider centrally acting agent (clonidine patch weekly or guanfacine at bedtime) 5

Next options:

• Hydralazine 25 mg three times daily, titrate to maximum dose
• Minoxidil 2.5 mg twice daily (reserve for truly refractory cases; requires loop diuretic and beta-blocker to prevent fluid retention and reflex tachycardia) 5

Step 4: Emerging Therapies (Under Investigation)

For selected patients with resistant hypertension:

• Aldosterone synthase inhibitors (baxdrostat) - promising Phase 2 data
• Dual endothelin receptor antagonists (aprocitentan) - shown efficacy in trials
• Non-steroidal MRAs (finerenone, esaxerenone) - particularly for CKD patients with albuminuria 9, 10, 11

Step 5: Device-Based Therapy (Highly Selected Patients)

Catheter-based renal denervation may be considered if:

• BP uncontrolled despite optimal 3-drug combination
• Performed at medium-to-high volume center
• After shared decision-making and multidisciplinary assessment
• Evidence remains evolving; not first-line therapy 1, 4

Baroreflex activation therapy - insufficient evidence for routine recommendation 4, 5

Key Monitoring and Follow-Up

• Assess target organ damage: LVH, proteinuria, reduced eGFR, retinopathy, peripheral arterial disease 5
• Monitor electrolytes and renal function at least annually, more frequently when adding MRAs 1, 2
• Use ABPM or HBPM for medication titration and confirming control 6, 12
• Screen for primary aldosteronism in all resistant hypertension patients (aldosterone-to-renin ratio) 12, 2

Common Pitfalls to Avoid

1. Using HCTZ instead of chlorthalidone/indapamide - thiazide-like diuretics are significantly more effective 2, 5
2. Combining ACE inhibitor + ARB - increases adverse events without additional benefit 8, 13
3. Adding spironolactone with eGFR <45 or K+ >4.5 - high risk of hyperkalemia 1, 7
4. Failing to confirm with out-of-office BP - up to 50% have pseudoresistance 6, 7
5. Not screening for obstructive sleep apnea - present in majority of resistant cases and treatable 6, 2
6. Clinical inertia - failing to uptitrate medications to maximal tolerated doses 6, 5

Special Populations

Chronic Kidney Disease (eGFR 30-45):

• Use loop diuretics instead of thiazides if significant volume overload
• Lower-dose spironolactone (12.5-25 mg) with close monitoring
• Consider finerenone if albuminuria present 1, 2

Diabetes:

• Target BP 120-129/80 mmHg if tolerated
• RAS blocker essential if albuminuria present
• SGLT2 inhibitors provide modest additional BP lowering 1, 13

Elderly (>75 years):

• Same BP targets if community-dwelling and functional
• Individualize for frail patients with multiple comorbidities and falls 4